Supreme Court rejects appeals from drugmakers over Medicare price negotiations
The Supreme Court has upheld the legality of Medicare drug price negotiations, rejecting appeals from pharmaceutical companies. This decision maintains the federal government's ability to negotiate prices as established by the 2022 Inflation Reduction Act. The program aims to lower costs for certain high-cost drugs for Medicare beneficiaries, with the first agreements set to take effect in 2026.
- ▪The Supreme Court rejected appeals from drug manufacturers regarding Medicare price negotiations.
- ▪The negotiation program was created by the 2022 Inflation Reduction Act, allowing the government to negotiate drug prices.
- ▪So far, the government has negotiated prices for 25 prescription drugs covered by Medicare.
Opening excerpt (first ~120 words) tap to expand
ABC NewsLiveVideoShowsGood Morning AmericaShopGMAInterest Successfully AddedWe'll notify you here with news aboutTurn on desktop notifications for breaking stories about interest? OffOnStream onSupreme Court rejects appeals from drugmakers over Medicare price negotiationsThe Supreme Court has rejected appeals from pharmaceutical companies that object to negotiating Medicare drug prices with the federal governmentByMARK SHERMAN Associated Press and ALI SWENSON Associated PressMay 18, 2026, 9:43 AM1:48A statue titled the "Authority of Law" sits in front of the Supreme Court on Friday, May 15, 2026, in Washington.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at ABC News — US.
Discussion
0 commentsMore from ABC News — US
